<DOC>
	<DOC>NCT01152567</DOC>
	<brief_summary>The planned Study will be a retrospective study on the effect of ACE's vs. candesartan on cardiovascular events and on health economic effects in a "real life" setting in Sweden.</brief_summary>
	<brief_title>Effects of Angiotensin Converting Enzyme (ACE) Inhibitors Versus Candesartan in Reducing Cardiovascular Events in Primary Treatment of Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<criteria>all patients found in electronic patient journals at the participating centres, who were prescribed either ACEis (ATCC09AB) or ARBs (C09CD) for hypertension from 1 January 1999 31 December 2007. The first date of such a prescription starts the observation time and is called the index prescription. No history of cardiovascular disease. Ongoing malignancy</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>ACE</keyword>
	<keyword>ARB</keyword>
	<keyword>real life data</keyword>
	<keyword>CVD</keyword>
	<keyword>cost effectiveness</keyword>
</DOC>